Loading
LO
Loxo Oncology, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Naider Avi Z., was filed 17 Dec 2018.
Loxo Oncology, Inc.: what insiders have been doing
Loxo Oncology, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Loxo Oncology, Inc. in twelve months, the latest record being from 15 February 2019.
The full history, which starts in 2016, counts 3 purchases against 449 sales.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
569
Thresholds
n/a
Buy Volume
€9M
3 ops. · all time
Sell Volume
€462M
449 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2017FY ended December 2017 · cache
Income statement
Net income-132.7M
Last declaration on 15 February 2019
Declarations569 total
30,000 shares@ US$235.008.8% of flowCommon StockSEC:0001567619-19-004566:1
18,896 shares@ US$235.00100.0% of flowCommon StockSEC:0001567619-19-004575:0
111,843 shares@ US$235.0094.7% of flowCommon StockSEC:0001567619-19-004574:1
9,732 shares@ US$235.0021.5% of flowCommon StockSEC:0001567619-19-004569:0
19,000 shares@ US$235.0030.2% of flowCommon StockSEC:0001567619-19-004576:0
162,707 shares@ US$235.0048.0% of flowCommon StockSEC:0001567619-19-004566:0
15,000 shares0Common StockSEC:0001567619-19-004574:0
2,038,920 shares@ US$235.00100.0% of flowCommon StockSEC:0001567619-19-004568:0
725 shares@ US$138.920.4% of flowCommon StockSEC:0001567619-18-008134:0
Canonical exit: 13 Mar 2019 (T+90)
1,250 shares@ US$11.350.4% of flowCommon StockSEC:0001567619-18-007785:0
100 shares@ US$130.790.4% of flowCommon StockSEC:0001567619-18-007785:1
400 shares@ US$132.441.4% of flowCommon StockSEC:0001567619-18-007785:2
100 shares@ US$133.340.4% of flowCommon StockSEC:0001567619-18-007785:3
550 shares@ US$134.712.0% of flowCommon StockSEC:0001567619-18-007785:4
100 shares@ US$136.040.4% of flowCommon StockSEC:0001567619-18-007785:5
1,250 shares@ US$11.350.4% of flowCommon StockSEC:0001567619-18-007785:6
200 shares@ US$135.690.7% of flowCommon StockSEC:0001567619-18-007785:7
587 shares@ US$136.982.2% of flowCommon StockSEC:0001567619-18-007785:8
100 shares@ US$139.360.4% of flowCommon StockSEC:0001567619-18-007785:10
100 shares@ US$140.480.4% of flowCommon StockSEC:0001567619-18-007785:11
1,000 shares@ US$132.230.9% of flowCommon StockSEC:0001567619-18-007788:2
900 shares@ US$133.170.8% of flowCommon StockSEC:0001567619-18-007788:3
1,400 shares@ US$134.651.2% of flowCommon StockSEC:0001567619-18-007788:4
500 shares@ US$135.140.4% of flowCommon StockSEC:0001567619-18-007788:5
200 shares@ US$136.480.2% of flowCommon StockSEC:0001567619-18-007788:6
25 of 569 declarations
About Loxo Oncology, Inc.
Loxo Oncology, Inc. is a biopharmaceutical company focused on developing targeted therapies for specific cancers. It emphasizes innovation in oncology through genomics-based approaches.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
